EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Circulating tumor DNA as a biomarker in early phase clinical trials

Harold N Tan, Mitchell J Elliott, Ian M Silverman, Lillian L Siu, Timothy A Yap

Cancer Cell · 2026-02 · 44 (2) · 240-247

DOI: 10.1016/j.ccell.2025.11.011 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Cell, 2026-02. Verfasst von Harold N Tan und 4 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Biomarkers, Tumor, Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: AstraZeneca, Daiichi-Sankyo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The clinical development of novel cancer therapeutics is rapidly evolving with the integration of molecular biomarkers to advance precision medicine. Circulating tumor DNA (ctDNA) represents a versatile tool to detect targetable alterations, predict therapeutic response, monitor tumor evolution, and inform pharmacokinetic and pharmacodynamic effects. This could accelerate early phase drug development and deepen our understanding of biological drivers of response and resistance. Herein, we highlight current applications and future opportunities for ctDNA as a multi-utility biomarker in early phase clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNABiomarkers, TumorNeoplasmsHumansClinical Trials as TopicPrecision Medicine

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Foundation Medicine Inc., Boston, MA, USA.
  • University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: tyap@mdanderson.org.

Förderung

  • AstraZeneca
  • Daiichi-Sankyo

Zitieren

APA

Tan, H. N., Elliott, M. J., Silverman, I. M., Siu, L. L., & Yap, T. A. (2026). Circulating tumor DNA as a biomarker in early phase clinical trials. Cancer Cell, 44(2), 240-247. https://doi.org/10.1016/j.ccell.2025.11.011

Vancouver

Tan HN, Elliott MJ, Silverman IM, Siu LL, Yap TA. Circulating tumor DNA as a biomarker in early phase clinical trials. Cancer Cell. 2026;44(2):240-247. doi:10.1016/j.ccell.2025.11.011

BibTeX
@article{Tan2026,
  author = {Tan, Harold N and Elliott, Mitchell J and Silverman, Ian M and Siu, Lillian L and Yap, Timothy A},
  title = {Circulating tumor DNA as a biomarker in early phase clinical trials},
  journal = {Cancer Cell},
  year = {2026},
  volume = {44},
  number = {2},
  pages = {240--247},
  doi = {10.1016/j.ccell.2025.11.011}
}
Kostenlos starten →